Accès gratuit
Med Sci (Paris)
Volume 20, Numéro 6-7, Juin-Juillet 2004
Page(s) 685 - 690
Section M/S revues
Publié en ligne 15 juin 2004
  1. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis : Basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91 : 2488–96. [Google Scholar]
  2. Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247 : 349–58. [Google Scholar]
  3. Lusis AJ. Atherosclerosis. Nature 2000; 407 : 233–41. [Google Scholar]
  4. Assmann G, Cullen P, Jossa F, et al. Coronary heart disease : Reducing the risk : The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease. Arterioscler Thromb Vasc Biol 1999; 19 : 1819–24. [Google Scholar]
  5. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium : Triumphs, concerns, and opportunities. N Engl J Med 1997; 337 : 1360–9. [Google Scholar]
  6. Russell DW. Cholesterol biosynthesis and metabolism. Cardiovasc Drugs Ther 1992; 6 : 103–10. [Google Scholar]
  7. Ros E. Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 2000; 151 : 357–79. [Google Scholar]
  8. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137 : S101–9. [Google Scholar]
  9. Davignon J. Advances in drug treatment of dyslipidemia : Focus on atorvastatin. Can J Cardiol 1998; 14 (suppl B) : 28B–38. [Google Scholar]
  10. Farnier M, Davignon J. Current and future treatment of hyperlipidemia : The role of statins. Am J Cardiol 1998; 82 : 3J–10. [Google Scholar]
  11. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials : A meta-analysis. Arch Intern Med 1999; 159 : 1793–802. [Google Scholar]
  12. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98 : 2088–93. [Google Scholar]
  13. van Heek M, Davis H. Pharmacology of ezetimibe. Eur Heart J 2002; 4 (suppl) : J5–8. [Google Scholar]
  14. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy. The role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003; 107 : 3124–8. [Google Scholar]
  15. Sleight P. Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 2002; 89 : 11A–7. [Google Scholar]
  16. Evans M, Roberts A, Rees A. The future direction of cholesterol-lowering therapy. Curr Opin Lipidol 2002; 13 : 663–9. [Google Scholar]
  17. Brousseau ME, Schaefer EJ. New targets for medical treatment of lipid disorders. Curr Atheroscler Rep 2002; 4 : 343–9. [Google Scholar]
  18. Brown WV. Therapies on the horizon for cholesterol reduction. Clin Cardiol 2001; 24 : III24–7. [Google Scholar]
  19. Thompson GR, Naoumova RP. New prospects for lipid-lowering drugs. Exp Opin Invest Drugs 1998; 7 : 715–27. [Google Scholar]
  20. Pharmaproject. Richmond, Surrey (UK) : PJB Publications, 2003. [Google Scholar]
  21. Ugawa T, Kakuta H, Moritani H, et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol 2000; 131 : 63–70. [Google Scholar]
  22. Chevy F, Illien F, Wolf C, Roux C. Limb malformations of rat fetuses exposed to a distal inhibitor of cholesterol biosynthesis. J Lipid Res 2002; 43 : 1192–200. [Google Scholar]
  23. Chang G, Ruggeri RB, Harwood HJ, Jr. Microsomal triglyceride transfer protein (MTP) inhibitors : Discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. Curr Opin Drug Discov Dev 2002; 5 : 562–70. [Google Scholar]
  24. Shiomi M, Ito T. MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol 2001; 431 : 127–31. [Google Scholar]
  25. Nicolosi RJ, Wilson TA, Krause BR. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis 1998; 137 : 77–85. [Google Scholar]
  26. Accad M, Smith SJ, Newland DL, et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA : Cholesterol acyltransferase 1. J Clin Invest 2000; 105 : 711–9. [Google Scholar]
  27. Willner EL, Tow B, Buhman KK, et al. Deficiency of acyl CoA : Cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2003; 100 : 1262–7. [Google Scholar]
  28. Brewer HB Jr. The lipid-laden foam cell : An elusive target for therapeutic intervention. J Clin Invest 2000; 105 : 703–5. [Google Scholar]
  29. Ichihashi T, Izawa M, Miyata K, et al. Mechanism of hypocholesterolemic action of S-8921 in rats : S-8921 inhibits ileal bile acid absorption. J Pharmacol Exp Ther 1998; 284 : 43–50. [Google Scholar]
  30. Izzat NN, Deshazer ME, Loose-Mitchell DS. New molecular targets for cholesterol-lowering therapy. J Pharmacol Exp Ther 2000; 293 : 315–20. [Google Scholar]
  31. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97 : 2917–23. [Google Scholar]
  32. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406 : 203–7. [Google Scholar]
  33. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans : A randomized phase II dose-response study. Circulation 2002; 105 : 2159–65. [Google Scholar]
  34. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289 : 1524–9. [Google Scholar]
  35. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002; 99 : 7604–9. [Google Scholar]
  36. Lund EG, Menke JG, Sparrow CP. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23 : 1169–77. [Google Scholar]
  37. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22 : 717–26. [Google Scholar]
  38. Klappacher GW, Glass CK. Roles of peroxisome proliferator-activated receptor gamma in lipid homeostasis and inflammatory responses of macrophages. Curr Opin Lipidol 2002; 13 : 305–12. [Google Scholar]
  39. Meng CQ, Somers PK, Rachita CL, et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett 2002; 12 : 2545–8. [Google Scholar]
  40. Mashima R, Witting PK, Stocker R. Oxidants and antioxidants in atherosclerosis. Curr Opin Lipidol 2001; 12 : 411–8. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.